Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Narrative Review

Vol. 4 No. 1 (1998)

Antimicrobial Resistant Streptococcus pneumoniae Infections: Clinical and Epidemiological Trends

  • James D. Kellner, M.D., M.Sc., F.R.C.P.(C)
  • Donald E. Low, M.D., F.R.C.P.(C)
DOI
https://doi.org/10.26443/mjm.v4i1.677
Submitted
November 8, 2020
Published
2020-12-01

Abstract

N/A

References

  1. Report of the Director-General. The World Health Report: Life in the 21st Century - A Vision for All. Geneva: World Health Organization; 1998.
  2. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 275: 189-193; 1996.
  3. Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era (and others). Science 257: 1050-1082; 1992.
  4. Bax RP, Anderson R, Crew J, et al. Antibiotic resistance - what can we do? Nature Medicine 4: 545-546; 1998.
  5. Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. Journal of Pediatrics 107: 382-387; 1985.
  6. Morris A, Kellner JD, Low DE. The superbugs: evolution, dissemination and fitness. Current Opinion in Infectious Diseases 12, in press.
  7. Obaro SK, Monteil MA, Henderson DC. The pneumococcal problem. British Medical Journal 312: 1521-1525; 1996.
  8. Peter G, Klein JO. Streptococcus pneumoniae. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. New York: Churchill Livingstone; 1997: 828-835.
  9. Voss L, Lennon D, Okesene-Gafa K, et al. Invasive pneumococcal disease in a pediatric population, Auckland, New Zealand. Pediatric Infectious Disease Journal 13: 873-878; 1994.
  10. Eskola J, Takala AK, Kola E, et al. Epidemiology of invasive pneumococcal infections in Finland. JAMA 268: 3323-3327; 1992.
  11. Dagan R, Engelhard D, Piccard E, et al. Epidemiology of invasive childhood pneumococcal infections in Israel. JAMA 268: 3328-3332; 1992.
  12. Zangwill KM, Vadheim CM, Vannier AM, et al. Epidemiology of invasive pneumococcal disease in Southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. Journal of Infectious Diseases 174: 752-759, 1996.
  13. Torzillo PJ, Hanna JN, Morey F, et al. Invasive pneumococcal disease in central Australia. Medical Journal of Australia 162: 182-186; 1995.
  14. Davidson M, Parkinson AJ, Bulkow LR, et al. The Epidemiology of invasive pneumococcal disease in Alaska, 1986-1990 - ethnic differences and opportunities for prevention. Journal of Infectious Diseases 170: 368-376; 1994.
  15. McGeer A, Landry L, Goldenberg E, et al. Population-based surveillance for invasive pneumococcal infections in Toronto, Canada: implications for prevention. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans: American Society for Microbiology, Abstract K009; 1996.
  16. Iverson BG. Epidemiology of invasive bacterial infections caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Streptococcus pyogenes in Norway 1982-1995, and the influence of Haemophilus influenzae type b conjugate vaccine on their occurrence: analysis of national surveillance data. London: London School of Hygiene and Tropical Medicine; 1996.
  17. Nielsen SV, Henrichsen J. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94. Edpidemiology and Infection 117: 411-416; 1996.
  18. Hedlund J, Svenson SB, Kalin M, et al. Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. Clinical Infectious Diseases 21: 948- 953; 1995.
  19. Baer M, Vuento R, Vesikari T. Increase in bacteraemic pneumococcal infections in children [Letter]. Lancet 345: 661; 1995.
  20. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1997.
  21. Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinal Surveillance System. Journal of Infectious Diseases 174: 986-993; 1996.
  22. Klugman KP. Pneumococcal resistance to antibiotics. Clinical Microbiology Reviews 3: 171-196; 1990.
  23. Moreillon P, Markiewicz Z, Nachman S, et al. Two bacterial targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms. Antimicrobial Agents and Chemotherapy 34: 33-39; 1990.
  24. Neu HC. The crisis in antibiotic resistance. Science 257: 1064- 1073; 1992.
  25. McDougal LK, Rasheed JK, Biddle JW, et al. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrobial Agents and Chemotherapy 39: 2282-2288; 1995.
  26. Simor AE, Louie M, Low DE. The Canadian Bacterial Surveillance Network. Canadian national survey of prevalence of antibiotic resistance among clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 40: 2190-2193; 1996.
  27. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. New England Journal of Medicine 333: 481-486; 1995.
  28. Spratt BG. Antibiotic resistance: counting the cost. Current Biology 6: 1219-1221; 1996.
  29. Friedland IR, McCracken Jr. GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. New England Journal of Medicine 331: 377-382; 1994.
  30. Eriksen KR. Studies on induced resistance to penicillin in a pneumococcus type I. Acta Pathologica et Microbiologica 22: 398-405; 1945.
  31. Kislak JW, Razavi LMB, Daly AK, et al. Susceptibility of pneumococci to nine antibiotics. American Journal of Medical Science 54: 261-268; 1965.
  32. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 2: 264-265; 1967.
  33. Appelbaum PC. World-wide development of antibiotic resistance in pneumococci. European Journal of Clinical Microbiology 6: 367-377; 1987.
  34. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of mulitply resistant pneumococci. New England Journal of Medicine 299: 735-740; 1978.
  35. Doern GV, Brueggemann A, Holley HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40: 1208-1213; 1996.
  36. Spika JS, Facklam RR, Plikaytis BD, et al. Pneumococcus Surveillance Working Group. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. Journal of Infectious Diseases 163: 1273-1278; 1991.
  37. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug- resistant pneumococcal infections in the United States. JAMA 271: 1831-1835; 1994.
  38. Centers for Disease Control and Prevention. Drug-resistant Streptococcus pneumoniae - Kentucky and Tennessee, 1993. Mortality and Morbidity Weekly Report 43: 23-25; 1994.
  39. Lee HJ, Park JY, Jang SH, et al. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clinical Infectious Diseases 20: 826-835; 1995.
  40. Marton A. Pneumococcal antimicrobial resistance: the problem in Hungary. Clinical Infectious Diseases 15: 106-111; 1992.
  41. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. American Journal of Diseases of Children 146: 920-923; 1992.
  42. Garcia-Leoni ME, Cercenado E, Rodeño P, et al. Susceptibility of Streptococcus pneumoniae to penicillin: a prospective microbiological and clinical study. Clinical Infectious Diseases 14: 427-435; 1992.
  43. Kam KM, Luey KY, Fung SM, et al. Emergence of multiple- antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrobial Agents and Chemotherapy 39: 2667-2670; 1995.
  44. Yoshida R, Kaku M, Kohno S, et al. Trends in antimicrobial resistance of Streptococcus pneumoniae in Japan. Antimicrobial Agents and Chemotherapy 39: 1196-1198; 1995.
  45. Setchanova L. Clinical isolates and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in hospital for infectious diseases, Sofia, Bulgaria, 1991-1993. Antimicrobial Drug Resistance 1: 7984; 1995.
  46. Marchese A, Debbia EA, Arvigo A, et al. Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics. Journal of Antimicrobial Chemotherapy 36: 833-837; 1995.
  47. Mittermayer H, Jebelean C, Binder L, et al. Antibiotic susceptibility of pneumococci isolated in Austria over a four-year period. European Journal of Clinical Microbiology and Infectious Diseases 15: 817-820, 1996.
  48. Ahronheim GA, Reich B, Marks MI. Penicillin-insensitive pneumococci. American Journal of Diseases of Children 133: 187-191; 1979.
  49. Pabst HF, Nigrin J. Penicillin resistance of pneumococci and immune deficiency. Lancet 2: 359-360; 1979.
  50. Dixon JMS, Lipinski AE, Graham MEP. Detection and prevalence of pneumococci with increased resistance to penicillin. Canadian Medical Association Journal 117: 1159-1161; 1977.
  51. Jetté LP, Lamothe F, and The Pneumococcus Study Group. Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada from 1984 to 1986: serotype distribution, antimicrobial susceptibility and clinical characteristics. Journal of Clinical Microbiology 27: 1-5; 1989.
  52. Scheifele D, Gold R, Talbot J, et al. A national survey of invasive pneumococcal infections in children. Infectious Diseases Society of America Annual Meeting, San Francisco Abstract 410; 1995.
  53. Simor AE, Rachlis A, Louie L, et al. Emergence of penicillin-resistant Streptococcus pneumoniae in southern Ontario, 1993-94. Canadian Journal of Infectious Diseases 6: 157-160; 1995.
  54. Scheifele D, Gold R, Marchessault V, et al. Penicillin resistance among invasive pneumococcal isolates at 10 children's hospitals, 1991-1994. Canada Communicable Disease Report 22; 1996.
  55. Kellner JD, McGeer A, Cetron MS, et al. The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatric Infectious Disease Journal 17: 279-286; 1998.
  56. Takala AK, Jero J, Kela E, et al. Risk factors for primary invasive pneumococcal disease among children in Finland. JAMA 273: 859-864; 1995.
  57. Andiman WA, Mezeger J, Shapiro E. Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. Journal of Pediatrics 124: 846-852; 1994.
  58. Black S, Shinefield H, Elvin L, et al. Pneumococcal epidemiology in childhood in a large HMO population. 34th Interconference on Antimicrobial Agents and Chemotherapy. Orlando: American Society for Micrbiology Abstract G71; 1994.
  59. Farley JJ, King JC Jr, Nair P, et al. Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. Journal of Pediatrics 124: 853-858; 1994.
  60. Gessner BD, Ussery XT, Parkinson AJ, et al. Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaska native children younger than two years of age. Pediatric Infectious Disease Journal 14: 123-128; 1995.
  61. Fekety Jr JR, Caldwell J, Gump D, et al. Bacteria, viruses, and mycoplasmas in acute pneumonia in adults. American Review of Respiratory Disease 104: 499-507; 1971.
  62. Lipsky BA, Boyko EJ, Inui TS, et al. Risk factors for acquiring pneumococcal infections. Archives of Internal Medicine 146: 2179-2185; 1986.
  63. Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. Journal of Pediatrics 109: 579-585; 1986.
  64. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committtee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 46: 1-25; 1997.
  65. Nava JM, Bella F, Garau J, et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clinical Infectious Diseases 19: 884-90; 1994.
  66. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatric Infectious Disease Journal 14: 885-890; 1995.
  67. Jackson MA, Shelton S, Nelson JD, et al. Relatively penicillin-resistant pneumococcal infections in pediatric patients. Pediatric Infectious Disease Journal 3: 129-132; 1984.
  68. Reichler MR, Rakovsky J, Sobotová A, et al. Multiple antimicrobial resistance of pneumococci in children with otitis media, bacteremia, and meningitis in Slovakia. Journal of Infectious Diseases 171: 1491-1496; 1995.
  69. Bédos JP, Chevret S, Chastang C, et al. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with reduced susceptibility to penicillin: findings of a French survey. Clinical Infectious Diseases 22: 63-72; 1996.
  70. Welby PL, Keller DS, Cromien JL, et al. Resistance to penicillin and non-beta-lactam antibiotics of Streptococcus pneumoniae at a children's hospital. Pediatric Infectious Disease Journal 13:281-287; 1994.
  71. Block SL, Harrison CJ, Hedrick JA, et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, suscepibility patterns and antimicrobial management. Pediatric Infectious Disease Journal 14: 751-759; 1995.
  72. Pallares R, Gudiol F, Liñares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. New England Journal of Medicine 317: 18-22; 1987.
  73. Tan TQ, Mason EO, Kaplan SH. Penicillin-resistant systemic pneumococcal infections in children: a retrospective case-control study. Pediatrics 92: 761-767; 1993.
  74. Mannheimer SB, Riley LW, Roberts RB. Association of penicillin-resistant pneumococci with residence in a pediatric chronic care facility. Journal of Infectious Diseases 174: 513-519; 1996.
  75. Gómez J, Baños V, Gómez JR, et al. Clinical significance of pneumococcal bacteraemias in a general hospital: a prospective study 1989-1993. Journal of Antimicrobial Therapy 36: 1021- 1030; 1995.
  76. Kronenberger CB, Hoffman RE, Lezotte DC, et al. Invasive penicillin-resistant pneumococcal infections: a prevalence and historical cohort study. Emerging Infectious Diseases 2: 121-124; 1996.
  77. Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumoniae in Barcelona, Spain (published erratum appears in New England Journal of Medicine 333: 1655; 1995). New England Journal of Medicine 333: 474-480; 1995.
  78. Tan TQ, Mason EO, Kaplan SL. Systemic infections due to Streptococcus pneumoniae relatively resistant to penicillin in a children's hospital: clinical management and outcome. Pediatrics 90: 928-933, 1992.
  79. John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clinical Infectious Diseases 18: 188-193; 1994.
  80. Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatric Infectious Disease Journal 15: 980-985; 1996.
  81. Barry B, Gehanno P, Blumen M, et al. Clinical outcome of acute otitis media caused by pneumococci with decreased susceptibility to penicillin. Scandinavian Journal of Infectious Diseases 26: 446-452; 1994.
  82. Bradley JS, Kaplan SL, Klugman KP, et al. Consensus: management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin. Pediatric Infectious Disease Journal 14: 1037-1041; 1995.
  83. Paris M, Ramilio O, McCracken GH. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 39: 2171-2175; 1995.
  84. American Academy of Pediatrics Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Pediatrics 99: 289-299; 1997.
  85. Doit C, Barre J, Cohen R, et al. Bactericidal activity against intermediately cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with bacterial meningitis treated with high dose of cefotaxime and vancomycin. Antimicrobial Agents and Chemotherapy 41: 2050-2052; 1997.
  86. Klugman KP, Friedland I, Bradley J. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrobial Agents and Chemotherapy 39: 1988-1992; 1995.
  87. Pikis A, Akram S, Donkersloot JA, et al. Penicillin-resistant pneumococci from pediatric patients in the Washington, DC, area. Archives of Pediatric and Adolescent Medicine 149: 30-35; 1995.
  88. Goldstein FW, Garau J. 30 years of penicillin-resistant S. pneumoniae: myth or reality? Lancet 350: 233; 1997.
  89. Klugman KP. Epidemiology, control and treatment of multiresistant pneumococci. Drugs 52 (Supplement 2): 42-46; 1996.
  90. Strachan SA, Friedland IR. Therapy for penicillin-resistant Streptococcus pneumoniae. Journal of Medical Microbiology 43: 237-238; 1995.
  91. Goldstein FW. Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae. Scandinavian Journal of Infectious Diseases 29: 255-257; 1997.
  92. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Journal of Chemotherapy 9 (Supplement 3): 38- 44; 1997.
  93. Craig WA. Antimicrobial resistance issues of the future. Diagnostic Microbiology and Infectious Disease 25: 213-217; 1996.
  94. Coffey TJ, Dowson CG, Daniels M, et al. Horizontal transfer of multiple penicillin binding protein genes, and capsular biosynthetic genes in natural populations of Streptococcus pneumoniae. Molecular Microbiology 5: 2255-2260; 1991.
  95. Appelbaum PC. New prospects for antibacterial agents against multidrug-resistant pneumococci. Microbial Drug Resistance 1: 43-48; 1995.
  96. Craig WA. Pharmacokinetics/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26: 1-12; 1998.
  97. Bryan CS, Talwani R, Stinson MS. Penicillin dosing for pneumococcal pneumonia. Chest 112: 1657-1664; 1997.
  98. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrobial Agents and Chemotherapy 39: 577- 585; 1995.
  99. Courvalin P, Ounissi H, Arthur M. Multiplicity of macrolide-lincosamide-streptogramin antibiotic resistance determinants. Journal of Antimicrobial Chemotherapy 16 (Supplement A): 91-100; 1985.
  100. Low DE. Quinipristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Microbial Drug Resistance 1: 223-224; 1995.
  101. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrobial Agents and chemotherapy 40: 1817-1824; 1996. 102. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrobial Agents and Chemotherapy 40: 2562-2566; 1996.
  102. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society Guidelines for outpatients with community-acquired pneumonia. JAMA 278: 32-39; 1997.
  103. Moreno S, Garcia-Leoni ME, Cercenado E, et al. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clinical Infectious Diseases 20: 1195-1200; 1995.
  104. Johnston NJ, de Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in Streptococcus pneumoniae from across Canada. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract. Toronto: American Society for Microbiology, 1997.
  105. Johnston NJ, de Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 42: 2415-2426; 1998.
  106. Yao JDO, Moellering RCJ. Antibacterial Agents. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. Washington: American Society for Microbiology Press; 1995: 1281-1307.
  107. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrobial Agents and Chemotherapy 40: 2375-2379; 1996.
  108. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine 336: 243-250; 1997.
  109. Zeller V, Janoir C, Kitzis MD, et al. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 41: 1973-1978; 1997.
  110. Pan XS, Ambler J, Mehtar S, et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 40: 2321-2326; 1996.
  111. Tankovic J, Perichon B, Duval J, et al. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrobial Agents and Chemotherapy 40: 2505-2510; 1996.
  112. Wise R, Brenwald N, Gill M, et al. Streptococcus pneumoniae resistance to fluoroquinolones [Letter]. Lancet 348: 1660; 1996.
  113. Piddock LJ. New quinolones and gram-positive bacteria. Antimicrobial Agents and Chemotherapy 38: 163-169; 1994.
  114. Adams M, Sullivan J, Henry D, et al. Comparison of grepafloxacin with cefaclor in the treatment of community- acquired pneumonia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract. Toronto: American Society for Microbiology Press; 1997.
  115. Graham DR, Klein T, Torres A, et al. A double blind, randomized, multicenter study of nosocomial pneumonia (NOS) comparing trovafloxacin with ciprofloxacin ±
  116. clindamycin/metronidazole. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: American Society for Microbiology Press; 1997.
  117. Mandell LA, Hopkins WD, Hopkins S. Efficacy of trovafloxacin in patients with community-acquired pneumonia due to penicillin-susceptible and resistant S. pneumoniae. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: American Society for Microbiology Press; 1997.
  118. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41: 1965-1972; 1997.
  119. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatric Infectious Disease Journal 14: 1-9; 1995.
  120. Levy SB. The challenge of antibiotic resistance. Scientific American 278: 46-53; 1998.

Downloads

Download data is not yet available.